AstraZeneca reports HICKORY Phase III results for AstraZeneca stock
Published on 10/14/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHICKORY results shape the next catalyst
- HICKORY produced a 17.05-meter benefit versus placebo on October 11, 2026.
- Second-quarter revenue reached USD 15.38 billion, up 6.40 percent year over year.
- AstraZeneca stock trades at EUR 141.95 at 12:04 p.m. CEST at Lang & Schwarz on October 14, 2026.
- Third-quarter results are scheduled for October 30, 2026.
AstraZeneca (GB0009895292) reported on October 11, 2026 that its HICKORY Phase III trial showed a 17.05-meter improvement versus placebo in the Six-Minute Walk Test. The result did not achieve statistical significance, giving AstraZeneca stock a mixed clinical signal rather than a clean approval catalyst.
HICKORY delivers a measured result
According to AstraZeneca, efzimfotase alfa produced the 17.05-meter least-squares mean difference at week 25, with a p-value of 0.1675. A post hoc analysis found that 45.20 percent of treated patients reached the minimum clinically important difference, versus 30.00 percent for placebo.
The trial enrolled 124 patients across 17 countries. The company also reported a 5.74-point improvement in the FACIT-Fatigue secondary endpoint and continued improvement through week 49, while emphasizing the investigational status of efzimfotase alfa.
What does the pipeline add?
The commercial context remains substantial. MarketBeat reported that second-quarter 2026 revenue rose 6.40 percent year over year to USD 15.38 billion, while earnings per share of USD 2.63 exceeded the USD 2.50 consensus. Revenue was slightly below the USD 15.44 billion estimate.
Chronology is clear: on October 5, 2026, AstraZeneca completed its USD 2.00 billion equity investment in Summit Therapeutics, according to AstraZeneca; on October 7, 2026, Yahoo Finance reported that Jefferies kept a Buy rating and a GBp 17,500 price target; on October 11, 2026, AstraZeneca published the HICKORY data.
Which dates matter next?
AstraZeneca's investor-relations calendar lists the ESMO management event for October 26, 2026 and third-quarter and nine-month results for October 30, 2026. The results date is the next direct test of whether the pipeline investment and commercial portfolio are translating into operating momentum.
Stock price and valuation context
AstraZeneca stock was trading at EUR 141.95 at Lang & Schwarz on October 14, 2026 at 12:04 p.m. CEST. The primary listing is on the London Stock Exchange, where the stock was last quoted at USD 155.82 on October 13, 2026, with a 52-week range of USD 153.41 to USD 212.71 and a market capitalization of USD 241.7 billion.
The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of October 14, 2026, 12:04 p.m. CEST): EUR 141.95
- Market capitalization: USD 241.7 billion (as of October 13, 2026)
- 52-week range: USD 153.41-212.71 (as of October 13, 2026)
- Sector / Industry: Health care / Pharmaceuticals
- Index membership: FTSE 100
- Next earnings date: October 30, 2026
Market context: Market report FTSE 100.
